Literature DB >> 9987534

Gradually progressive dementia without discrete cerebrovascular events in a patient with Sneddon's syndrome.

R A Wright1, E Kokmen.   

Abstract

A 37-year-old man sought medical advice because of an 8-year history of a slowly progressive dementing illness with no clinically apparent discrete strokelike episodes. Cognitive functioning was markedly, globally impaired without lateralizing or localizing features. Widespread livedo reticularis led to a diagnosis of Sneddon's syndrome. Antiphospholipid antibodies and lupus anticoagulant were negative. Magnetic resonance imaging showed widespread cerebral atrophy, cortical and subcortical cerebral infarcts, and extensive periventricular white matter abnormalities. Cerebral angiography revealed diffuse medium- and small-vessel occlusive disease, with numerous collaterals in the mid and distal circulation but no evidence of atherosclerosis or vasculitis. No other cause of a dementing illness was found. We postulate that our patient's dementia was due to the cumulative effects of multiple cerebral infarcts.

Entities:  

Mesh:

Year:  1999        PMID: 9987534     DOI: 10.4065/74.1.57

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  3 in total

1.  Improvement of neurological symptoms and memory and emotional status in a case of seronegative Sneddon syndrome with cyclophosphamide.

Authors:  Peter M Hannon; Sheng-Han Kuo; Adriana M Strutt; Michele K York; Joseph S Kass
Journal:  Clin Neurol Neurosurg       Date:  2010-05-04       Impact factor: 1.876

2.  A rarely seen syndrome in rehabilitation of hemiplegia: antiphospholipid antibody-negative Sneddon's syndrome.

Authors:  Ayla Akbal; Aydan Kurtaran; Barin Selçuk; Murat Ersöz; Müfit Akyüz
Journal:  Rheumatol Int       Date:  2009-08-21       Impact factor: 2.631

Review 3.  Vascular dementia: a review of recent evidence for prevention and treatment.

Authors:  Howard S Kirshner
Journal:  Curr Neurol Neurosci Rep       Date:  2009-11       Impact factor: 5.081

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.